Glaukos
San Clemente
About Glaukos
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $100K – $500K
- Total funding: $121.0M
- Funding stage: IPO
- Last round: Series F (Feb 2013)
- Ticker: nyse:GKOS
- Website: glaukos.com
- Phone: 19493679984
Industries & Categories
Health Care, Medical, Wellness
Social Profiles
Canonical: https://fsome.com/organization/glaukos-2212507 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.